Impaired de novo NAD
+ biosynthesis predisposes to acute kidney injury, and augmenting NAD + metabolism with oral nicotinamide supplementation may prevent acute kidney injury.
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O ver one-fifth of all hospitalized patients develop acute kidney injury (AKI), a condition that has been defined as an abrupt decline in renal function. The incidence of AKI is highest in patients admitted to intensive care unit (ICU) (32%) and in patients undergoing cardiac surgery (24%) 1 . AKI-associated all-cause mortality occurs in 23% of hospitalized patients, and depending on its severity, AKI confers a risk of death three to seven times higher than that for patients without the condition 1 . AKI that is severe enough to require renal replacement therapy (RRT; dialysis or kidney transplantation) occurs in 2.3% of all hospitalized patients, increasing the risk of death by 24-fold 1 . As there is currently no effective therapy for preventing AKI, there is an urgent unmet medical need to discover new renoprotective therapies for improving clinical outcomes in patients with AKI.
Nicotinamide 4 provide three key findings for patients at risk of developing aKi. The authors have uncovered a new mechanism underlying AKI by identifying in kidneys subjected to transient ischemia that reduced levels of QPRT result in impaired renal de novo biosynthesis of NAD + and predispose to AKI. This metabolic defect increased uQ/T levels, providing a potential new biomarker for identifying patients at risk of AKI and for predicting adverse clinical outcomes. Finally, the authors have demonstrated that augmenting renal NAD + metabolism with oral nicotinamide (a precursor of NAD + ) could prevent AKI, providing a potential new therapy for preventing AKI and improving clinical outcomes in patients admitted to ICU or undergoing cardiac surgery. DM, diabetes mellitus; CKD, chronic kidney disease.
Next, the authors investigated whether impaired de novo NAD + biosynthesis linked to QPRT also occurs during transient renal ischemia in adult patients undergoing cardiac surgery. AKI occurs in 24% of these patients 1 , with modest rises in postoperative serum creatinine (a measure of kidney function) being associated with higher 30-day mortality 5, 6 . Patients with AKI who require RRT have in-hospital mortality rates as high as 60% (ref. 7 ). In a small cohort of six patients undergoing cardiac surgery on cardiopulmonary bypass who developed postoperative AKI, the authors demonstrated that uQ/T significantly increased at 24 h and persisted for 5 days following surgery in comparison to 6 patients who underwent cardiac surgery but did not develop AKI. In a separate large prospective study of 215 patients admitted to ICU, the authors found that elevations in urinary quinolinate and uQ/T occurred at a median of 2.5 days before the diagnosis of AKI. Importantly, levels of uQ/T were able to identify patients at risk of developing AKI and to predict adverse clinical outcomes (severe AKI, RRT-and AKI-related death and in-hospital death). These findings suggest that a deficient QPRT may contribute to the development of AKI in humans, and that uQ/T may be a new biomarker for detection of AKI and for prediction of adverse outcomes in patients admitted to ICU.
The authors next tested the safety and tolerability of oral nicotinamide administration in human volunteers as a potential therapy for AKI. A 3-day course of high-dose (3 g per day) oral nicotinamide was well-tolerated, led to detectable levels of circulating nicotinamide and was not nephrotoxic (as it did not affect kidney function) in a small group of healthy volunteers (n = 8). They went on to carry out a phase 1 randomized controlled trial of oral nicotinamide versus placebo in adults undergoing cardiac surgery to assess its safety and tolerability. The study comprised three treatment groups: nicotinamide at 1 g per day (n = 13), 3 g per day (n = 14) and placebo (n = 14), administered orally or via a nasogastric tube on days -1, 0 and + 1, which were the day before, the day of and the day after surgery, respectively. Blood and urine nicotinamide levels were significantly higher in patients receiving nicotinamide, and the side-effect profile was no different to placebo. Although this study was not designed to test the efficacy of nicotinamide for treating AKI, the latter did significantly reduce postoperative levels of serum cardiac troponin-T and serum creatinine levels over the 3-day postoperative period, suggesting a potential cardioprotective and renoprotective effect.
The findings from the study by Mehr et al. 4 suggest that reduced levels of kidney NAD + due to impaired de novo NAD + biosynthesis as a result of impaired function of QPRT predisposes affected individuals to AKI (Fig. 1) . Further studies are needed to elucidate the mechanisms through which kidney levels of QPRT are reduced following the acute insult. uQ/T levels in urine may be a new biomarker for identification of patients at risk of AKI, and it may also predict adverse clinical outcomes in patients admitted to ICU. Further work is needed to assess the robustness of uQ/T as a biomarker for early detection of AKI and for predicting adverse clinical outcomes, and to investigate how its performance as a biomarker compares with other AKI biomarkers, such as neutrophil gelatinaseassociated lipocalin 8 . Finally, administration of oral nicotinamide to augment renal NAD + metabolism is safe and tolerable in patients undergoing cardiac surgery, and it has the therapeutic potential to be renoprotective. Whether nicotinamide can prevent AKI and improve clinical outcomes in patients undergoing cardiac surgery and those admitted to ICU, needs to be investigated in large, adequately powered randomized clinical trials. Nicotinamide may be a promising and low-cost therapy for preventing AKI, and it may also have the therapeutic potential to protect other organs against acute injury, such as the heart in acute myocardial infarction, the brain following stroke and the liver during hepatic surgery. 
